Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arcellx, Inc. - Common Stock (NQ: ACLX ) 51.65 +1.63 (+3.26%) Streaming Delayed Price Updated: 1:41 PM EDT, May 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 177,174 Open 50.27 Bid (Size) 51.59 (2) Ask (Size) 51.74 (2) Prev. Close 50.02 Today's Range 50.19 - 51.77 52wk Range 30.74 - 75.10 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Peering Into Arcellx's Recent Short Interest April 15, 2024 Via Benzinga Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference April 04, 2024 From Arcellx, Inc. Via Business Wire Performance YTD -8.01% -8.01% 1 Month -22.89% -22.89% 3 Month -18.84% -18.84% 6 Month +46.52% +46.52% 1 Year +17.87% +17.87% More News Read More Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference March 20, 2024 From Arcellx, Inc. Via Business Wire Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley March 07, 2024 Via Benzinga Arcellx Analysts Boost Their Forecasts After Q4 Results February 29, 2024 Via Benzinga Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know January 04, 2024 Via Benzinga Where Arcellx Stands With Analysts December 11, 2023 Via Benzinga The 3 Biotech Stocks That Could Make Your February Unforgettable February 15, 2024 Via InvestorPlace Decoding Bearish Analog And The Warning Signs You Can't Ignore February 07, 2024 Via Talk Markets Topics Stocks Exposures US Equities Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market January 16, 2024 Via InvestorPlace Exposures Product Safety Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 January 04, 2024 Via Benzinga Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development December 15, 2023 Via InvestorPlace Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session December 12, 2023 Via Benzinga Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say December 11, 2023 Via Benzinga Chart Of The Day: Arcellx - Reimagining Cell Therapy December 08, 2023 Via Talk Markets 3 Biotech Stocks That Could Be Multibaggers in the Making November 30, 2023 Via InvestorPlace Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead November 15, 2023 Via Investor's Business Daily Kite and Arcellx Announce Expansion in Strategic Partnership November 15, 2023 From Gilead Sciences, Inc. Via Business Wire Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today? November 02, 2023 Via Benzinga 7 Biotech Stocks to Get In Now Before Investors Catch On October 23, 2023 Via InvestorPlace Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session November 02, 2023 Via Benzinga Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday November 02, 2023 Via Benzinga Topics Stocks Exposures US Equities Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs October 02, 2023 Via InvestorPlace Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential August 15, 2023 Via Benzinga Exposures Product Safety Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 October 17, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
